Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-19. Check what remains unresolved below before relying on it.
What does this change in the investment case for Teva Pharmaceutical Industries?
Demonstrated reduction in hospitalizations and emergency room visits supports formulary tier placement and commercial volume adoption for TEVA.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factTeva announced real-world comparative data for UZEDY (risperidone extended-release injectable). |
| What else was confirmed? | Reported factThe study showed superior treatment continuity compared to other long-acting injectables in schizophrenia and oral antipsychotics in bipolar I disorder. |
| Does the valuation support acting? | Interpretation3 stored valuation assumptions for TEVA; the latest is dated 2026-09-11. |
| What would change the assessment? | UnknownTeva specialty pharma branded revenue tracking in upcoming Q3 report — IMS/IQVIA prescription volume data for UZEDY. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Teva announced real-world comparative data for UZEDY (risperidone extended-release injectable).
- · The study showed superior treatment continuity compared to other long-acting injectables in schizophrenia and oral antipsychotics in bipolar I disorder.
- · UZEDY treatment resulted in reduced emergency care utilization and overall healthcare costs.
Public research record
Research framework · page evidenceCompleted event assessment
commercial formulary access expansion and specialty pharma revenue growth
| Type | Claim | Scope |
|---|---|---|
| Assumption | Teva announced real-world comparative data for UZEDY (risperidone extended-release injectable). | 2026-09-19 |
| Interpretation | commercial formulary access expansion and specialty pharma revenue growth | TEVA |
Countercase, invalidators, and sources
PBMs upgrade UZEDY formulary coverage status, accelerating quarterly prescription growth.
- · Teva specialty pharma branded revenue tracking in upcoming Q3 report — IMS/IQVIA prescription volume data for UZEDY.
- Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables · 2026-09-18
What remains unresolved
- Base path
- UZEDY continues steady market-share gains in hospital discharge protocols.
- Adverse path
- Payer reimbursement negotiations demand higher gross-to-net rebates.
- Supportive path
- PBMs upgrade UZEDY formulary coverage status, accelerating quarterly prescription growth.
- · Teva specialty pharma branded revenue tracking in upcoming Q3 report — IMS/IQVIA prescription volume data for UZEDY.this week
Evidence
- Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables2026-09-18
“Teva announced real-world data demonstrating that UZEDY (risperidone) extended-release injectable suspension shows superior treatment continuity compared to other long-acting injectables in schizophrenia patients and oral antipsychotics in bipolar I disorder. The data revealed UZEDY reduced emergency care...”
Supports: UZEDY demonstrated superior treatment continuity and reduced emergency care healthcare costs.